Guselkumab (an IL-23–specific mAb) demonstrates clinical and molecular response in patients with moderate-to-severe psoriasis-Reference-Cited by-同舟云学术

Guselkumab (an IL-23–specific mAb) demonstrates clinical and molecular response in patients with moderate-to-severe psoriasis

Published:2014-04 Issue:4 Volume:133 Page:1032-1040
ISSN:0091-6749
Container-title:Journal of Allergy and Clinical Immunology
language:en
Short-container-title:Journal of Allergy and Clinical Immunology

Author:

Sofen Howard,Smith Stacy,Matheson Robert T.,Leonardi Craig L.,Calderon Cesar,Brodmerkel Carrie,Li Katherine,Campbell Kim,Marciniak Stanley J.,Wasfi Yasmine,Wang Yuhua,Szapary Philippe,Krueger James G.

Publisher

Elsevier BV

Subject

Immunology,Immunology and Allergy

Reference29 articles.

1. Psoriasis pathophysiology: current concepts of pathogenesis;Krueger;Ann Rheum Dis,2005

2. Pathogenesis and therapy of psoriasis;Lowes;Nature,2007

3. The IL-23/T17 pathogenic axis in psoriasis is amplified by keratinocyte responses;Lowes;Trends Immunol,2013

4. Expanding the psoriasis disease profile: interrogation of the skin and serum of patients with moderate-to-severe psoriasis;Suarez-Farinas;J Invest Dermatol,2012

5. Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation of the brain;Cua;Nature,2003

Cited by 275 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Differential Pharmacodynamic Effects on Psoriatic Biomarkers by Guselkumab Versus Secukinumab Correlate with Long-Term Efficacy: An ECLIPSE Substudy;JID Innovations;2024-09

2. Guselkumab Reduces Disease- and Mechanism-Related Biomarkers More Than Adalimumab in Patients with Psoriasis: A VOYAGE 1 Substudy;JID Innovations;2024-09

3. Treatment strategies for Spondyloarthritis: Implementation of precision medicine – Or “one size fits all” concept?;Autoimmunity Reviews;2024-09

4. Noninferiority of 16-Week vs 8-Week Guselkumab Dosing in Super Responders for Maintaining Control of Psoriasis;JAMA Dermatology;2024-07-31

5. Guselkumab - In Psoriasis and Beyond;Dermatology Practical & Conceptual;2024-07-31